Celcuity Inc (NASDAQ:CELC) reported a narrower-than-expected loss for the second quarter on Thursday.
The company posted quarterly losses of $1.07 per share which beat the analyst consensus estimate of losses of $1.17 per share. This represents a 15.05% decline over losses of 93 cents per share from the same period last year.
“Celcuity made monumental progress these past few months, achieving critical clinical and regulatory milestones related to gedatolisib. With the FDA approval of REVTORPYK, positive results from the PIK3CA MT cohort of the pivotal VIKTORIA-1 study, and a preferred Category 1 recommendation in the NCCN Guidelines®, we are well positioned to address a significant unmet need for the tens of thousands of patients affected each year by HR+/HER2-, locally advanced or metastatic breast cancer whose disease has progressed after endocrine therapy,” said Brian Sullivan, CEO and co-founder of Celcuity. “We are on track to begin shipping REVTORPYK late in the third quarter of 2026, and we look forward to making this important therapy available to patients with locally advanced or metastatic breast cancer.”
Celcuity shares rose 0.7% to $87.17 in pre-market trading.
These analysts made changes to their price targets on Celcuity following earnings announcement.
- Needham analyst Gil Blum maintained the stock with a Buy and lowered the price target from $157 to $140.
- Stifel analyst Stephen Willey maintained the stock with a Buy and cut the price target from $175 to $150.
Considering buying CELC stock? Here’s what analysts think:
Photo via Shutterstock